Evidence map›Paper›PMID 37886561›Full record

ArticleResearch square2023

Anionic Nanoplastic Contaminants Promote Parkinson's Disease-Associated α-Synuclein Aggregation.

Zhiyong Liu, Arpine Sokratian, Addison M Duda, Enquan Xu, Christina Stanhope, Amber Fu, Samuel Strader, Huizhong Li, Yuan Yuan, Benjamin G Bobay and 8 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Zhiyong LiuDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Arpine SokratianDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Addison M DudaDepartment of Chemistry, Duke University, Durham, NC, USA.
Enquan XuDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Christina StanhopeDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Amber FuDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Samuel StraderDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Huizhong LiDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Yuan YuanDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Benjamin G BobayDepartment of Chemistry, Duke University, Durham, NC, USA.
Joana SipeDepartment of Civil and Environmental Engineering, Duke University, Durham, NC, USA.
Ketty BaiDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Iben LundgaardDepartment of Experimental Medical Science, Lund University, Lund, Sweden.
Na LiuDepartment of Experimental Medical Science, Lund University, Lund, Sweden.
Belinda HernandezDepartment of Ophthalmology and Cell Biology, Duke University, Durham, NC, USA.
Catherine Bowes RickmanDepartment of Ophthalmology and Cell Biology, Duke University, Durham, NC, USA.
Sara E MillerDepartment of Pathology, Duke University, Durham, North Carolina, USA.
Andrew B WestDuke Center for Neurodegeneration and Neurotheraputics, Duke University, Durham, NC, USA.
Duke University · USLund University · SE

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Vadim Y Arshavsky · 1985 to 2026
$19.3M
Project 3: LRRK2 mediated macrophage responses in PDP50NS108675 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STANDAERT, DAVID G. · 2018 to 2022
$9.9M
Training Program in Developmental & Stem Cell BiologyT32HD040372 · NICHD · DUKE UNIVERSITY · PI Terry H Lechler · 2001 to 2026
$8.9M
Mechanisms of LRRK2 Mediated NeurotoxicityR01NS064934 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2010 to 2025
$6.3M
Pharmacological Sciences Training ProgramT32GM133352 · NIGMS · DUKE UNIVERSITY · PI Cynthia M Kuhn, David M MacAlpine · 2020 to 2026
$3.8M
Complement factor H modulates lipoprotein clearance in AMDR01EY031748 · NEI · DUKE UNIVERSITY · PI BOWES RICKMAN, CATHERINE · 2020 to 2024
$2.8M
Role of Rab10 in Alzheimer's diseaseK99AG075179 · NIA · DUKE UNIVERSITY · PI LIU, ZHIYONG · 2022 to 2023
$219k
RPE Exosomes in Age-related Macular DegenerationF31EY033170 · NEI · DUKE UNIVERSITY · PI HERNANDEZ, BELINDA J · 2021 to 2024
$91k
NEI NIH HHS F31 EY033170NEI NIH HHS P30 EY005722NEI NIH HHS R01 EY031748NIA NIH HHS K99 AG075179NICHD NIH HHS T32 HD040372NIGMS NIH HHS T32 GM133352NINDS NIH HHS P50 NS108675NINDS NIH HHS R01 NS064934
6 · The paper itself

Abstract

Recent studies have identified increasing levels of nanoplastic pollution in the environment. Here we find that anionic nanoplastic contaminants potently precipitate the formation and propagation of α-synuclein protein fibrils through a high-affinity interaction with the amphipathic and non-amyloid component (NAC) domains in α-synuclein. Nanoplastics can internalize in neurons through clathrin-dependent endocytosis, causing a mild lysosomal impairment that slows the degradation of aggregated α-synuclein. In mice, nanoplastics combine with α-synuclein fibrils to exacerbate the spread of α-synuclein pathology across interconnected vulnerable brain regions, including the strong induction of α-synuclein inclusions in dopaminergic neurons in the substantia nigra. These results highlight a potential link for further exploration between nanoplastic pollution and α-synuclein aggregation associated with Parkinson's disease and related dementias.

Indexed as

microplasticsneurodegenerationprotein aggregation

Identifiers

PMID37886561
PMCPMC10602106
OpenAlexW4387566237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.